Nrx pharmaceuticals announces potent antibacterial activity of nrx-101 against common, antibiotic resistant urinary pathogens

Nrx-101 demonstrated potent antibacterial effect against antibiotic-resistant pathogens in culture medium and in an artificial urine model d-cycloserine (dcs), a key component of nrx-101, was originally developed as an anti-infective in the 1950's but was replaced by antibiotics that have since lost effectiveness against complicated urinary tract infections (cuti) in an era when 90% of cuti pathogens demonstrate resistance to standard antibiotics, nrx-101 may prove effective in treating cuti and preventing urosepsis radnor, pa. , sept. 6, 2023 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate potent in vitro activity of nrx-101 (d-cycloserine + lurasidone) against reference strains of urinary tract pathogens known to cause complicated urinary tract infections (cutis).
NRXP Ratings Summary
NRXP Quant Ranking